Nivolumab
Anticancer medication
Ratings
0
Nobody has rated this yet. Be the first!
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
Nivolumab plus ipilimumab in advanced melanoma